Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Specter of eye toxicity looms over BCMA-targeted therapy

Nature Biotechnology volume 38, pages 1363–1365 (2020)Cite this article

The first antibody–drug conjugate to treat multiple myeloma can spur reversible loss of vision, but that may not be the case for other anti-BCMA T-cell therapies or bispecific antibodies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Somerville, MA, USA

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Specter of eye toxicity looms over BCMA-targeted therapy. Nat Biotechnol 38, 1363–1365 (2020). https://doi.org/10.1038/s41587-020-00757-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-00757-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing